Key facts
- Supira Medical’s last known valuation is $445.0M (Mar 2025).
- It has raised $241.0M across 6 recorded rounds; the latest was Later Stage VC ($120.0M) in Mar 2025.
- Notable investors include Novo Holdings, Qatar Investment Authority, Cormorant Asset Management, TCP Health Ventures, 415 Capital — 10 tracked in total.
- Supira Medical has filed 6 Form Ds with the SEC since 2017, most recently Apr 2025 ($120.0M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Supira Medical
Funding rounds
6 roundsAbout Supira Medical
Developer of a percutaneous ventricular assist device designed to treat high-risk coronary interventions and cardiogenic shock. The company's device provides temporary mechanical support for severe coronary artery disease or comorbidities to treat patients suffering from cardiogenic shock, enabling patients to recover from heart problems.
- Sector
- Healthcare
- HQ
- Los Gatos, CA, United States
- Founded
- 2012
- Employees
- 125
- Website
- supiramedical.com/
- Ownership
- Privately Held (backing)
Supira Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Supira Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Supira Medical in its N-PORT filings yet. We sweep new filings monthly.